Skip to main content
Article thumbnail
Location of Repository

The Sequence Alteration Associated with a Mutational Hotspot in p53 Protects Cells From Lysis by Cytotoxic T Lymphocytes Specific for a Flanking Peptide Epitope

By Matthias Theobald, Thomas Ruppert, Ulrike Kuckelkorn, Javier Hernandez, Annett Häussler, Edite Antunes Ferreira, Ulrike Liewer, Judith Biggs, Arnold J. Levine, Christoph Huber, Ulrich H. Koszinowski, Peter-M. Kloetzel and Linda A. Sherman

Abstract

A high proportion of tumors arise due to mutation of the p53 tumor suppressor protein. A p53 hotspot mutation at amino acid position 273 from R to H, flanking a peptide epitope that spans residues 264–272, renders cells resistant to killing by human histocompatibility leukocyte antigen (HLA)-A*0201–restricted cytotoxic T lymphocytes (CTLs) specific for this epitope. Acquisition of the R to H mutation at residue 273 of the human p53 protein promotes tumor growth in vivo by selective escape from recognition by p53.264–272 peptide-specific CTLs. Synthetic 27-mer p53 polypeptides covering the antigenic nonamer region 264–272 of p53 were used as proteasome substrates to investigate whether the R to H mutation at the P1′ position of the COOH terminus of the epitope affects proteasome-mediated processing of the protein. Analysis of the generated products by tandem mass spectrometry and the kinetics of polypeptide processing in conjunction with CTL assays demonstrate that the R to H mutation alters proteasomal processing of the p53 protein by inhibiting proteolytic cleavage between residues 272 and 273. This prevents the release of the natural CTL epitope that spans flanking residues 264–272 as well as a putative precursor peptide. These results demonstrate that mutation of p53 not only leads to malignant transformation but may also, in some instances, affect immune surveillance and should be considered in the design of cancer vaccines

Topics: Articles
Publisher: The Rockefeller University Press
OAI identifier: oai:pubmedcentral.nih.gov:2212538
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (1996). a Flanking CTL Epitope squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide.
    2. (1994). A sequential model for peptide binding and transport by the transporters associated with antigen processing.
    3. (1996). A single residue exchange within a viral CTL epitope alters proteasome-mediated degradation resulting in lack of antigen presentation.
    4. (1996). A third interferon-g–induced subunit exchange in the 20S proteasome.
    5. (1994). Altered peptidase and viral-specific T cell response in LMP2 mutant mice.
    6. (1992). CD81 T cell recognition of an endogenously processed epitope is regulated primarily by residues within the epitope.
    7. Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non–self-protein, influenza matrix: relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides.
    8. (1995). Contribution of proteasome-mediated proteolysis to the hierarchy of epitopes presented by major histocompatibility complex class I molecules.
    9. (1996). Coordinated dual cleavages induced by the proteasome regulator PA28 lead to dominant MHC ligands.
    10. (1994). Differential effects of flanking residues on presentation of epitopes from chimeric peptides.
    11. (1994). Efficiency of MHC class I antigen processing: a quantitative analysis.
    12. (1991). Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein.
    13. (1994). Evidence for selection against human lung cancers bearing p53 missense mutations which occur within the HLA A*0201 peptide consensus motif. Cancer Res.
    14. Flanking residues alter antigenicity and immunogenicity of multi-unit CTL epitopes.
    15. (1992). Flanking sequences influence the presentation of an endogenously synthesized peptide to cytotoxic T lymphocytes.
    16. g-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes.
    17. (1993). Gain of function mutations in p53.
    18. (1995). Genes encoded in the major histocompatibility complex affecting the generation of peptides for TAP transport.
    19. (1997). Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD8.
    20. (1993). Identification of melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes.
    21. (1995). Immunobiology of cytotoxic T-cell escape mutants of lymphocytic choriomeningitis virus.
    22. (1993). In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53.
    23. (1996). In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res.
    24. (1995). Incorporation of major histocompatibility complex–encoded subunits LMP2 and LMP7 changes the quality of the 20S proteasome polypeptide processing products independent of interferon-g.
    25. (1994). Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules.
    26. (1994). Interferon g stimulation modulates the proteolytic activity and cleavage site preference of 20S mouse proteasomes.
    27. LMP21 proteasomes are required for the presentation of specific antigens to cytotoxic T lymphocytes.
    28. (1994). MHC class I expression in mice lacking the proteasome subunit
    29. (1997). MHC class I-associated peptides produced from endogenous gene products with vastly different efficiencies.
    30. (1994). MHC-encoded proteasome subunits LMP-2 and LMP-7 are not required for efficient antigen presentation.
    31. (1993). MHC-linked LMP gene products specifically alter peptidase activities of the proteasome.
    32. (1985). Mutations that impair a posttranscriptional step in expression of HLA-A and -B antigens.
    33. (1996). p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor challenge.
    34. p53 mutations in human cancers.
    35. (1994). p53, a potential target for tumor-directed T cells.
    36. (1994). Partial purification of murine tumor-associated peptide epitopes common to histologically distinct tumors, melanoma and sarcoma, that are presented by H-2Kb molecules and recognized by CD81 tumor-infiltrating lymphocytes.
    37. (1997). Patterns of immunodominance in HIV-1-specific cytotoxic T lymphocyte responses in two human histocompatibility leukocyte antigens (HLA)-identical siblings with HLA-A*0201 are influenced by epitope mutation.
    38. Peptidase activities of proteasomes are differentially regulated by the major histocompatibility complex–encoded genes for LMP-2 and LMP-7.
    39. Peptide antigen production by the proteasome: complexity provides efficiency.
    40. (1994). Peptide length and sequence specificity of the mouse TAP1/TAP2 translocator.
    41. Peptide size selection by the major histocompatibility complex-encoded peptide transporter.
    42. (1997). Point mutation flanking a CTL epitope ablates in vitro and in vivo recognition of a full-length viral protein.
    43. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection.
    44. (1997). Potential immunocompetence of proteolytic fragments produced by proteasomes before evolution of the vertebrate immune system.
    45. (1996). Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in p53.
    46. (1995). Presentation of endogenous peptide/MHC class I complexes is profoundly influenced by specific C-terminal flanking residues.
    47. (1996). Processing and delivery of peptides presented by MHC class I molecules.
    48. (1995). Processing of major histocompatibility class I–restricted antigens in the endoplasmic reticulum.
    49. (1992). Proteasome subunits encoded in the MHC are not generally required for the processing of peptides bound by MHC class I molecules.
    50. (1990). Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus.
    51. (1998). Strategies for tumor elimination by cytotoxic T lymphocytes.
    52. (1994). T cell responses and virus evolution: loss of HLA A11-restricted CTL epitopes in Epstein-Barr virus isolates from highly A11-positive populations by selective mutation of anchor residues.
    53. (1995). T-cell mediated cytotoxicity against p53-protein derived peptides in bulk and limiting dilution cultures of healthy donors.
    54. (1995). Targeting p53 as a general tumor antigen.
    55. (1995). The cleavage preference of the proteasome governs the yield of antigenic peptides.
    56. (1990). The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53.
    57. (1995). The interferon-gamma-inducible 11S regulator (PA28) and the LMP2/ LMP7 subunits govern the peptide production by the 20S proteasome in vitro.
    58. (1991). The p53 tumor suppressor gene.
    59. (1992). The proteasome subunits encoded by the major histocompatibility complex are not essential for antigen presentation.
    60. (1996). The proteolytic fragments generated by vertebrate proteasomes: structural relationships to major histocompatibility complex class I binding peptide.
    61. (1997). The subunits MECL-1 and LMP2 are mutually required for incorporation into the 20S proteasome.
    62. (1996). Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines.
    63. (1997). Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes.
    64. (1994). Trimming of antigenic peptides in an early secretory compartment.
    65. (1994). Trimming of TAP-translocated peptides in the endoplasmic reticulum and in the cytosol during recycling.
    66. (1997). Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes.
    67. (1997). Two distinct proteolytic processes in the generation of a major histocompatibility complex class I–presented peptide.
    68. (1994). Virus escape from CTL recognition.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.